Background: Alzheimer's Disease (AD) is the most common form of dementia and is considered to disproportionately affect underserved populations like Hispanics/Latinos. Most research available with AD markers such as inflammation and APOE4 has been conducted in predominantly White cohorts, leaving a dearth of knowledge relating APOE4 and inflammation in Hispanic/Latinos. Recent research also suggests inflammation and AD risk may be sex-specific. This study investigated the effects of race/ethnicity, sex/gender, and APOE4 on inflammatory markers.
Method: Using data from the Health and Aging Brain Study-Health Disparities (HABS-HD), we assessed group differences between APOE4 status, ethnicity, and sex on anti-inflammatory marker interleukin-10 covarying for age and education.
Result: The dataset included 817 Mexican Americans (65% women, 18% APOE4 carrier, mean age±SD=63.21±8.04 years) and 746 white participants (54% women, 30% APOE4 carrier, mean age±SD=68.59±8.70 years) (Table 1). We found two-way interactions between sex and race/ethnicity (p=0.03) on IL-10, driven by higher IL-10 levels in Mexican American men; sex and APOE4 status (p=0.001), driven by higher IL-10 among APOE4 carriers in men; and race/ethnicity and APOE4 status (p=0.001), driven by higher IL-10 levels APOE4 carriers among Mexican Americans (Figure 1A,B and C respectively).
Conclusion: IL-10 is an important anti-inflammatory modulator of glial activation, preventing inflammation-mediated neuronal degeneration under pathological conditions. It has multiple immunoregulatory effects such as in ability to inhibit the production of several inflammatory cytokines. These findings support previous studies demonstrating heightened systemic inflammation in APOE4 carriers, but little has been shown regarding their relationship with gender and ethnicity. This finding suggests the importance of examining differences that may exist between APOE4, sex, and inflammatory markers in Hispanics/Latinos. Future work will examine other inflammatory markers.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/alz.091862 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biophysical mapping of TREM2-ligand interactions reveals shared surfaces for engagement of multiple Alzheimer's disease ligands.
Mol Neurodegener
January 2025
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA.
TREM2 is a signaling receptor expressed on microglia that has emerged as an important drug target for Alzheimer's disease and other neurodegenerative diseases. While a number of TREM2 ligands have been identified, little is known regarding the structural details of how they engage. To better understand this, we created a protein library of 28 different TREM2 variants that could be used to map interactions with various ligands using biolayer interferometry.
View Article and Find Full Text PDFPrecuneus activity during retrieval is positively associated with amyloid burden in cognitively normal older carriers.
J Neurosci
January 2025
German Center for Neurodegenerative Diseases (DZNE), Magdeburg 39120, Germany
The precuneus is a site of early amyloid-beta (Aβ) accumulation. Previous cross-sectional studies reported increased precuneus fMRI activity in older adults with mild cognitive deficits or elevated Aβ. However, longitudinal studies in early Alzheimer's disease (AD) are lacking and the relationship to the Apolipoprotein-E () genotype is unclear.
View Article and Find Full Text PDFPatient stratification by genetic risk in Alzheimer's disease is only effective in the presence of phenotypic heterogeneity.
PLoS One
January 2025
Washington University School of Medicine, NeuroGenomics and Informatics Center, St. Louis, MO, United States of America.
Case-only designs in longitudinal cohorts are a valuable resource for identifying disease-relevant genes, pathways, and novel targets influencing disease progression. This is particularly relevant in Alzheimer's disease (AD), where longitudinal cohorts measure disease "progression," defined by rate of cognitive decline. Few of the identified drug targets for AD have been clinically tractable, and phenotypic heterogeneity is an obstacle to both clinical research and basic science.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Institute of Human Behaviour and Allied Sciences, Delhi, India.
Background: ApoE polymorphism especially APOE ε4 play a central role in AD pathophysiology through Aβ-dependent and Aβ-independent neuropathogenic pathway in the Alzheimer's disease.
Method: A cross-sectional study was performed on non diseased and diseased subjects with stroke from outpatient services of Neurology department of Institute of Human Behavior & Allied Sciences (IHBAS), New Delhi (India). Subjects diagnosed with various dementias including Alzheimer's disease, non AD dementias and dementia with Behavior & Psychological symptoms were taken.
Background: The immune system is substantially involved in the development and progression of age-related cognitive decline and Alzheimer's disease (AD).
Method: As genetic and environmental factors interactively impact these conditions, we investigated how risk factors such as APOE genotype, age, and sex influence immune activation markers and AD biomarkers in cerebrospinal fluid (CSF) in elderly individuals enrolled in the Mayo Clinic Study of Aging cohort. Among cognitively unimpaired individuals aged over 65 at the baseline visit (N=298), we measured 365 CSF immune activation markers using the proximity extension assay.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!